Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DRMA

DRMA - Dermata Therapeutics, Inc Stock Price, Fair Value and News

$2.54-0.04 (-1.55%)
Market Closed

82/100

DRMA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

82/100

DRMA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.26

Target 3M

$2.71

Target 6M

$2.93

DRMA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DRMA Price Action

Last 7 days

22.1%

Last 30 days

36.6%

Last 90 days

-25.9%

Trailing 12 Months

-79.5%

DRMA RSI Chart

DRMA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DRMA Valuation

Market Cap

2.6M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

2.16

Price/Free Cashflow

-0.28

DRMA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.26

Target 3M

$2.71

Target 6M

$2.93

DRMA Fundamentals

DRMA Revenue

Revenue (TTM)

1.4M

DRMA Earnings

Earnings (TTM)

-8.8M

Earnings Growth (Yr)

46.68%

Earnings Growth (Qtr)

0.54%

DRMA Profitability

Return on Equity

-223.42%

Return on Assets

-174.46%

Free Cashflow Yield

-354.81%

DRMA Investor Care

Shares Dilution (1Y)

402.98%

Diluted EPS (TTM)

29.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024546.1K845.0K1.1M1.4M
2023124.8K186.0K0247.2K
202200063.6K
Get all data in R, Python etc through our Historical Stock Data APIs

About Dermata Therapeutics, Inc

DRMA
Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
 CEO
 WEBSITEdermatarx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES8

Dermata Therapeutics, Inc Frequently Asked Questions

DRMA is the stock ticker symbol of Dermata Therapeutics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Dermata Therapeutics, Inc is 2.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DRMA's fair value in chart for subscribers.

The fair value guage provides a quick view whether DRMA is over valued or under valued. Whether Dermata Therapeutics, Inc is cheap or expensive depends on the assumptions which impact Dermata Therapeutics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRMA.

As of Wed Jan 28 2026, DRMA's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 2.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRMA PE ratio will change depending on the future growth rate expectations of investors.